Certara Welcomes Arjun Bedi to its Board of Directors
Certara has appointed Arjun Bedi to its Board of Directors. His life sciences expertise will…
Certara2026 年 3 月 12 日
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026
Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…
Certara2026 年 3 月 11 日
Certara Announces 2026 Certainty Event
CERTAINTY 2026: Explore AI-driven drug development and technological innovation at the leading biosimulation event for…
Certara2026 年 3 月 9 日
Virtual Control Groups, Actually: What SEND Makes Possible (and What It Doesn’t)
Learn how SEND enables virtual control groups using historical toxicology data, including key applications, challenges,…
Certara2026 年 3 月 4 日
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle Pillsbury2026 年 3 月 4 日
ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
Certara2026 年 3 月 3 日
On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…
Certara2026 年 2 月 26 日
